Keyword: Dr. Patrick Soon-Shiong
Soon-Shiong sued over "catch-and-kill" of Abraxane rival; Gottlieb reflects on tenure as FDA chief; and British biotech Artios nabs Lilly, AZ veteran.
Sorrento alleged Patrick Soon-Shiong bought its cancer med Cynviloq to stop the drug from getting to market and competing with Celgene's Abraxane.
The proposed settlement would effectively erase NantCell’s investment in Precision Biologics.
Patrick Soon-Shiong’s NantKwest unit has reported the first data for its “cancer memory vaccine,” but it has some analysts scratching their heads.
Billionaire Patrick Soon-Shiong is planning an IPO for his company focused on developing a cancer vaccine cocktail of biologics, according to reports.
The reduction, which amounts to about one-third of NantHealth’s headcount, will lower costs at the Patrick Soon-Shiong-helmed company.
NantCell has paid $13 million up front to license CytRx's orphan cancer drug aldoxorubicin.
Altor shareholders, revolting against Patrick Soon-Shiong's deal to buy the company, are going to court to block it.
Patrick Soon-Shiong's outfit NantCell will acquire Altor Bioscience for two bucks a share.
Patrick Soon-Shiong announced at ASCO that his biotech company wants to expand its cancer vaccine work.